ANAPTYSBIO INC's ticker is ANAB and the CUSIP is 032724106. A total of 116 filers reported holding ANAPTYSBIO INC in Q2 2023. The put-call ratio across all filers is 0.97 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,510 | -11.8% | 307 | 0.0% | 0.00% | – |
| Q2 2023 | $6,244 | -6.5% | 307 | 0.0% | 0.00% | – |
| Q1 2023 | $6,677 | -29.8% | 307 | 0.0% | 0.00% | – |
| Q4 2022 | $9,510 | +18.9% | 307 | 0.0% | 0.00% | – |
| Q3 2022 | $8,000 | +33.3% | 307 | 0.0% | 0.00% | – |
| Q2 2022 | $6,000 | -25.0% | 307 | 0.0% | 0.00% | – |
| Q1 2022 | $8,000 | -27.3% | 307 | 0.0% | 0.00% | – |
| Q4 2021 | $11,000 | -91.9% | 307 | -95.1% | 0.00% | -100.0% |
| Q1 2021 | $136,000 | +0.7% | 6,300 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $135,000 | +45.2% | 6,300 | 0.0% | 0.00% | +50.0% |
| Q3 2020 | $93,000 | -34.0% | 6,300 | 0.0% | 0.00% | -50.0% |
| Q2 2020 | $141,000 | +58.4% | 6,300 | 0.0% | 0.00% | +33.3% |
| Q1 2020 | $89,000 | -50.0% | 6,300 | +23.9% | 0.00% | -40.0% |
| Q3 2019 | $178,000 | -16.4% | 5,085 | +35.0% | 0.01% | -16.7% |
| Q2 2019 | $213,000 | – | 3,768 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 3,688,448 | $102,354,000 | 54.68% |
| Novo Holdings A/S | 3,033,504 | $84,180,000 | 8.96% |
| BVF INC/IL | 1,738,600 | $48,246,000 | 8.21% |
| Cormorant Asset Management, LP | 895,626 | $24,854,000 | 3.61% |
| Perceptive Advisors | 881,957 | $24,474,000 | 1.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 100,500 | $2,789,000 | 1.07% |
| ACUTA CAPITAL PARTNERS, LLC | 165,690 | $4,138,000 | 0.98% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 845,746 | $23,469,000 | 0.90% |
| Iguana Healthcare Management, LLC | 50,000 | $1,388,000 | 0.69% |
| Boxer Capital, LLC | 50,000 | $1,388,000 | 0.30% |